APOE and Alzheimer disease: This was indicated by the finding that the soluble Aβ42 levels were significantly increased in the AD patients with both APOE ε34 (p = 0.01) and ε44 genotypes (p = 0.00007) as compared to the ε33 genotype (Figure 3B).